Biogen Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIIB | AMGN | BMY | SAN.PA | 0QYQ.IL | NVS | |
|---|---|---|---|---|---|---|
| Market cap | 37.61B | 258.68B | 131.21B | 101.18B | 215.56B | 311.59B |
| P/E (TTM) | 110.2 | 27.7 | 14.2 | 25.4 | 39.8 | 31.5 |
| Forward P/E | 15.6 | 19.5 | 9.6 | 9.1 | — | 16.6 |
| Price/book | 2.0 | 18.0 | 5.6 | 1.4 | 10.2 | 8.4 |
| Dividend yield | — | 2.11% | 3.93% | 4.90% | 3.81% | 2.87% |
| 1-year change | +62.24% | +44.21% | +32.80% | −4.99% | +38.91% | +26.90% |
| Today | +2.22% | +3.73% | +4.02% | +0.42% | +0.58% | +3.59% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All BIIB news ›BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
BioCryst Q3 2026 beat estimates as Orladeyo grows, but competition and pipeline risks remain. Click here to read my most recent analysis. - BioCryst Pharmaceuticals delivered Q3 2026 results ahead of expectations, maintaining 2026 guidance…
Biocon banks on new biosimilar launches, insulin franchise to drive stronger H2 FY27
Biocon Ltd expects a significantly stronger second half of FY27, as momentum from recently launched biosimilars, robust insulin demand and a gradual recovery at Syngene International offset a weak September quarter. The company's profit…
Biocryst outlines $415M-$425M 2026 operating expense guidance while keeping ORLADEYO at $625M-$645M
BioCryst Q3 2026 earnings: ORLADEYO growth, pediatric launch, raised revenue outlook, and navenibart catalyst timing. Earnings Call Insights: BioCryst Pharmaceuticals (BCRX) Q3 2026 - "The third quarter was significant for BioCryst as we…
bit.bio Raises $25M in Series D Funding
FinSMEs bit.bio Raises $25M in Series D Funding bit.bio, a Cambridge, UK-based human cell programming company, raised $25M in Series D funding. Backers included M&G Investments and Dr. Jonathan Milner. The company intends to use the funds…
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Nick Wilder - Manager of Investor RelationsCharles Gayer - CEO, President & DirectorBabar Ghias - CFO & Head of Corporate DevelopmentSandeep Menon -…
Biogen’s tau drug diranersen gets a CTAD spotlight
Alzheimer’s research has spent decades on amyloid, the sticky protein that clumps between brain cells. Tau is the other suspect, and it gets less of the glory. Biogen plans to change that a little this month. The company will present new…
bit.bio raises $25M Series D as demand for its human cell models grows
Emma Pepperell CEO and Connie O’Donnell Director Marketing (from left). Cambridge-based biotech company bit.bio has raised $25M in a Series D round, ten months after securing its previous investment. The company announced the new funding…
Biogen Pharmachem Industries reports profit of ₹25.73 crore for Q2 2026
Biogen Pharmachem reports ₹25.73 lakh Q2 profit InvestyWise Biogen Pharmachem Industries reports profit of ₹25.73 crore for Q2 2026 Biogen Pharmachem Industries Limited has announced its unaudited financial results for the quarter and…
Bio-Techne downgraded by Wells Fargo with a new price target
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Bio-Techne downgraded by Wells…
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com43
- themarketsdaily.com27
- seekingalpha.com26
- markets.businessinsider.com21
- theglobeandmail.com16
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.